CD4 depletion increases survival of B7-H1
mice. Infected wild-type (WT) and B7-H1−/− mice treated with α-CD4 or control α-βgalactosidase (α-βgal) monoclonal antibody (mAb) at 4 and 6 days post-infection (p.i) were monitored for (A) clinical symptoms and (B) survival. Significant differences in clinical symptoms comparing control and CD4-depleted WT and B7-H1−/− groups, respectively, were determined by Wilcoxon matched pairs test. ** P<0.005. (C) Clinical symptoms and (D) survival of infected B7-H1−/− mice treated with α-CD8 or control α-βgal mAb at days −2, 0 and 7p.i.